WordNet

make (a garment) fuller by pleating or gathering
having the normally expected amount; "gives full measure"; "gives good measure"; "a good mile from here" (同)good
filled to satisfaction with food or drink; "a full stomach" (同)replete
complete in extent or degree and in every particular; "a full game"; "a total eclipse"; "a total disaster" (同)total
(of sound) having marked deepness and body; "full tones"; "a full voice"
beat for the purpose of cleaning and thickening; "full the cloth"
containing as much or as many as is possible or normal; "a full glass"; "a sky full of stars"; "a full life"; "the auditorium was full to overflowing"
(biochemistry) a drug that can combine with a receptor on a cell to produce a physiological reaction
a muscle that contracts while another relaxes; "when bending the elbow the biceps are the agonist"
someone involved in a contest or battle (as in an agon)

PrepTutorEJDIC

『いっぱいの』,満ちた / (数量が)『たくさんある』,たっぷりある / (程度・量・数などが)『完全な』 / 《名詞の前にのみ用いて》最大限の / 《名詞の前にのみ用いて》正式の,本格的な / 《補語にのみ用いて》(…で)(腹・胸・頭が)いっぱいの(で)《+『of』+『名』》 / (形・体の一部が)ふっくらした,盛り上がった / (衣服などが)ゆったりしている / 《名詞の前にのみ用いて》(声・におい・色が)豊かな,濃い / まともに / 非常に(very) / 全部;十分;絶頂

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/08/15 02:04:33」(JST)

wiki en

[Wiki en表示]

Agonists activating hypothetical receptors.

Efficacy spectrum of receptor ligands.

An agonist is a chemical that binds to a receptor and activates the receptor to produce a biological response. Whereas an agonist causes an action, an antagonist blocks the action of the agonist and an inverse agonist causes an action opposite to that of the agonist.

Types of agonists

Receptors can be activated by either endogenous (such as hormones and neurotransmitters) or exogenous (such as drugs) agonists, resulting in a biological response. A physiological agonist is a substance that creates the same bodily responses but does not bind to the same receptor.

An endogenous agonist for a particular receptor is a compound naturally produced by the body that binds to and activates that receptor. For example, the endogenous agonist for serotonin receptors is serotonin, and the endogenous agonist for dopamine receptors is dopamine.^[1]

A superagonist is a compound that is capable of producing a greater maximal response than the endogenous agonist for the target receptor, and thus has an efficacy of more than 100%. This does not necessarily mean that it is more potent than the endogenous agonist, but is rather a comparison of the maximum possible response that can be produced inside the cell following receptor binding.

Full agonists bind (have affinity for) and activate a receptor, producing full efficacy at that receptor. One example of a drug that acts as a full agonist is isoproterenol, which mimics the action of adrenaline at β adrenoreceptors. Another example is morphine, which mimics the actions of endorphins at μ-opioid receptors throughout the central nervous system.

Partial agonists (such as buspirone, aripiprazole, buprenorphine, or norclozapine) also bind and activate a given receptor, but have only partial efficacy at the receptor relative to a full agonist, even at maximal receptor occupancy. Agents like buprenorphine are used to treat opiate dependence for this reason, as they produce milder effects on the opioid receptor with lower dependence and abuse potential.

An inverse agonist is an agent that binds to the same receptor binding-site as an agonist for that receptor and inhibits the constitutive activity of the receptor. Inverse agonists exert the opposite pharmacological effect of a receptor agonist, not merely an absence of the agonist effect as seen with antagonist. An example is the cannabinoid inverse agonist rimonabant.

A co-agonist works with other co-agonists to produce the desired effect together. NMDA receptor activation requires the binding of both glutamate, glycine and D-serine co-agonists.

An irreversible agonist is a type of agonist that binds permanently to a receptor through the formation of covalent bonds. A few of these have been described.^[2]^[3]

A selective agonist is selective for a specific type of receptor. E.g. buspirone is a selective agonist for serotonin 5-HT1A.

New findings that broaden the conventional definition of pharmacology demonstrate that ligands can concurrently behave as agonist and antagonists at the same receptor, depending on effector pathways or tissue type. Terms that describe this phenomenon are "functional selectivity", "protean agonism",^[4]^[5] or selective receptor modulators.^[6]

Activity

Potency

The potency of an agonist is inversely related to its EC₅₀ value. The EC₅₀ can be measured for a given agonist by determining the concentration of agonist needed to elicit half of the maximum biological response of the agonist. The EC₅₀ value is useful for comparing the potency of drugs with similar efficacies producing physiologically similar effects. The smaller the EC₅₀ value, the greater the potency of the agonist, the lower the concentration of drug that is required to elicit the maximum biological response.

Therapeutic index

When a drug is used therapeutically, it is important to understand the margin of safety that exists between the dose needed for the desired effect and the dose that produces unwanted and possibly dangerous side-effects (measured by the TD₅₀, the dose that produces toxicity in 50% of individuals). This relationship, termed the therapeutic index, is defined as the ratio TD₅₀:ED₅₀. In general, the narrower this margin, the more likely it is that the drug will produce unwanted effects. The therapeutic index emphasizes the importance of the margin of safety, as distinct from the potency, in determining the usefulness of a drug.

Etymology

From the Greek αγωνιστής (agōnistēs), contestant; champion; rival < αγων (agōn), contest, combat; exertion, struggle < αγω (agō), I lead, lead towards, conduct; drive

References

^ Goodman and Gilman's Manual of Pharmacology and Therapeutics. (11th edition, 2008). p14. ISBN 0-07-144343-6
^ De Mey JGR, Compeer MG, Meens MJ (2009). "Endothelin-1, an Endogenous Irreversible Agonist in Search of an Allosteric Inhibitor". Mol Cell Pharmacol 1 (5): 246–257.
^ Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, Rasmussen SG, Choi HJ, Devree BT, Sunahara RK, Chae PS, Gellman SH, Dror RO, Shaw DE, Weis WI, Caffrey M, Gmeiner P, Kobilka BK (January 2013). "Structure and function of an irreversible agonist-β(2) adrenoceptor complex". Nature 469 (7329): 236–40. doi:10.1038/nature09665. PMC 3074335. PMID 21228876.
^ Kenakin T (March 2001). "Inverse, protean, and ligand-selective agonism: matters of receptor conformation". FASEB J. 15 (3): 598–611. doi:10.1096/fj.00-0438rev. PMID 11259378.
^ Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. (January 2007). "Functional selectivity and classical concepts of quantitative pharmacology". J. Pharmacol. Exp. Ther. 320 (1): 1–13. doi:10.1124/jpet.106.104463. PMID 16803859.
^ Smith CL, O'Malley BW (February 2004). "Coregulator function: a key to understanding tissue specificity of selective receptor modulators". Endocr. Rev. 25 (1): 45–71. doi:10.1210/er.2003-0023. PMID 14769827.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. Pharmacotherapy for opioid use disorder
2. パーキンソン病の薬理学的治療 pharmacologic treatment of parkinson disease
3. プロゲステロン受容体モジュレーター（PRM）の薬理学および作用機序 pharmacology and mechanism of action of progesterone receptor modulators prms
4. プロゲステロン受容体拮抗剤および選択的プロゲステロン受容体モジュレーターの治療使用および有害作用 therapeutic use and adverse effects of progesterone receptor antagonists and selective progesterone receptor modulators
5. 妊娠時のブプレノルフィン補充療法 buprenorphine substitution therapy in pregnancy

English Journal

The hepatocyte growth factor isoform NK2 activates motogenesis and survival but not proliferation due to lack of Akt activation.

Mungunsukh O1, Lee YH2, Bottaro DP2, Day RM3.
Cellular signalling.Cell Signal.2016 Aug;28(8):1114-23. doi: 10.1016/j.cellsig.2016.05.012. Epub 2016 May 17.
Hepatocyte growth factor (HGF) is a pleiotrophic factor involved in cellular proliferation, migration and morphogenesis. HGF is required for normal tissue and organ development during embryogenesis, but in the adult HGF has been demonstrated to drive normal tissue repair and inhibit fibrotic remodel
PMID 27224506

TLR21's agonists in combination with Aeromonas antigens synergistically up-regulate functional TLR21 and cytokine gene expression in yellowtail leucocytes.

Reyes-Becerril M1, Ascencio-Valle F1, Hirono I2, Kondo H2, Jirapongpairoj W2, Esteban MA3, Alamillo E1, Angulo C4.
Developmental and comparative immunology.Dev Comp Immunol.2016 Aug;61:107-15. doi: 10.1016/j.dci.2016.03.012. Epub 2016 Mar 15.
The purpose of this study was to characterize the TLR21 gene from yellowtail (Seriola lalandi) and its functional activity using TLR agonist stimulation and Aeromonas antigens. The TLR21 nucleotide sequence from yellowtail was obtained using the whole-genome shotgun sequencing method and bioinformat
PMID 26987525

Pediatric acute asthma exacerbations: Evaluation and management from emergency department to intensive care unit.

Pardue Jones B1, Fleming GM2, Otillio JK1, Asokan I3, Arnold DH1,4.
The Journal of asthma : official journal of the Association for the Care of Asthma.J Asthma.2016 Aug;53(6):607-17. doi: 10.3109/02770903.2015.1067323. Epub 2016 Apr 26.
OBJECTIVE: The goal of this report is to review available modalities for assessing and managing acute asthma exacerbations in pediatric patients, including some that are not included in current expert panel guidelines. While it is not our purpose to provide a comprehensive review of the National Ast
PMID 27116362

Japanese Journal

Overexpressed α7 nicotinic acetylcholine receptor inhibited proinflammatory cytokine release in NIH3T3 cells(GENETICS, MOLECULAR BIOLOGY, AND GENE ENGINEERING)

Li Dong-Jie,Tang Qiu,Shen Fu-Ming,Su Ding-Feng,Duan Jun-Li,Xi Tao
Journal of bioscience and bioengineering 108(2), 85-91, 2009-08
… Full-length α7nAChR gene was extracted from rat peritoneal macrophages, recombinant plasmid pIRES2-EGFP-α7nAChR was constructed, and then transfected to the mouse fibroblast cell line NIH3T3, a cell line expressing RIC-3. … Moreover, in this established cell line, PNU-282987, a selective α7nAChR agonist, exerted a stronger ability to reduce TNF-α release than nicotine. …
NAID 110007359748